Skin, Hair, and Nails by Pharmekal was withdrawn from the market. Users discuss alternative supplements and treatments like Minoxidil, finasteride, and RU58841.
RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.
The user has been using oral Dutasteride, RU58841, and Minoxidil for three years without success and is considering adding topical Finasteride or Dutasteride to target DHT both locally and systemically. Other users suggest sticking to a consistent treatment plan, exploring different combinations, and considering other factors like potential misdiagnosis or inconsistent medication use.
A user discusses starting nandrolone replacement therapy to stop hair loss and improve hair health, noting its benefits over finasteride. They report halted hair loss, improved skin, increased muscle, and a calm mood after three weeks.
A user reports using Hims (with finasteride and minoxidil), Kirkland Minoxidil 5%, RU58841, and derma stamping for hair loss and seeks feedback on their 9-week progress, particularly for growth around the temples and crown.
The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.
A 22-year-old male is using topical dutasteride, minoxidil, tretinoin, and microneedling for hair loss, experiencing some side effects like mild ball pain and initial shedding but seeing progress in hair thickness. He plans to increase the dutasteride dose and has tried various treatments, including finasteride and RU58841, with differing side effects.
The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.
The user experienced hair growth improvement using a 1.25mm microneedle weekly, oral finasteride, oral minoxidil, and rosemary oil. They plan to switch to generic finasteride and minoxidil for safety concerns.
A user shared their hair loss treatment routine, which includes oral finasteride 5 times a week and topical minoxidil twice a day, and plans to add microneedling. They reported positive results, with reduced bald spots and no side effects affecting libido or physical strength.
The conversation discusses a hair loss treatment regimen using Alfatradiol, Pyrilutamide, and Minoxidil. The user shares their current stack of these treatments.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
The conversation discusses using topical dutasteride from minoxidilmax for hair loss and the possibility of crowdfunding for DHT blood tests to check if the treatment goes systemic. The user plans to post before and after pictures.
PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.
The user started using 1mg finasteride and Regaine foam post-hair transplant, noticing significant hair growth at three months. They experienced testicular cramps as a side effect but no other issues, and are considering microneedling for further improvement.
The conversation is about a transgender individual's experience with hair regrowth using topical minoxidil and hormone replacement therapy (HRT), expressing concern about the slow growth and thin appearance of their hair. Some responses encourage patience and highlight the variability of results, while others discuss the role of HRT and its effects.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
The user is experiencing chronic folliculitis with scalp sores and is concerned about a receding hairline. They have tried various treatments including antibiotics, Nizoral 2% shampoo, and lifestyle changes, but are seeking further advice.
A user shared their successful hair regrowth journey using finasteride, oral minoxidil, and oral dutasteride, expressing gratitude for the support received. The conversation includes congratulations and encouragement from others.
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
The conversation is about a person's hair improvement after 14.5 months using RU58841 and Minoxidil topically at 50 mg each day, with noticeable hairline improvement but incomplete crown area recovery. The person struggles to take good pictures of their crown area.
A user's 3-month progress with a combination of finasteride, minoxidil and dermarolling for hair loss; other users shared their experiences and advice.
A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
A user is starting topical finasteride and minoxidil 3 times a week for hair loss and is experiencing high anxiety about the treatment's effectiveness and potential side effects. They are also taking vitamin D3 daily and are concerned about the application method and possible shedding.
KX-826 did not maintain hair loss prevention for users. Some switched to Pyrilutamide but returned to Minoxidil and RU58841 due to worsening conditions.
The user has high free testosterone and is still experiencing hair loss despite taking dutasteride and oral minoxidil for over three years. They are considering adding a topical anti-androgen like RU58841.